trending Market Intelligence /marketintelligence/en/news-insights/trending/1eym_h-ygw_u1hsgaceema2 content esgSubNav
In This List

Report: Bayer planning job cuts, outsourcing to bolster pharma unit

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


Report: Bayer planning job cuts, outsourcing to bolster pharma unit

Germany's Bayer Aktiengesellschaft is considering downsizing its drug research and development activities to give itself financial room to buy the rights to promising treatments from other biotech firms, Reuters reported, citing a person familiar with the matter.

The German giant is under pressure from investors to undertake licensing deals or make purchases to ensure the continued independence of its pharmaceutical division, the report said.

The $62.5 billion acquisition of Monsanto Co. has reshaped Bayer's revenue streams, giving greater prominence to the crop sciences unit which was in the shadow of the company's pharmaceutical and consumer health businesses.

The ongoing review is evaluating outsourcing drug testing services to cheaper contractors and will be complete in November, the news agency said.